A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer
This study is being done to evaluate the safety of combining two strategies called "cryoablation" and "immune therapy" in women with curable early stage breast cancer.
Breast Cancer
PROCEDURE: Cryoablation|DRUG: Ipilimumab|DRUG: Nivolumab
Number of Participants Evaluated for Adverse Events, Safety will be evaluated for all treated subjects using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events v4.0 (CTCAE)., 12 weeks after ipilimumab/nivolumab administration.
This study is being done to evaluate the safety of combining two strategies called "cryoablation" and "immune therapy" in women with curable early stage breast cancer.